[Echocardiographic indices of cardiac function and systemic hemodynamics in patients with cardiac fibrillation paroxysms and their dynamics as affected by disopyramide phosphate].
Clinical and echocardiographic studies in 25 chronic coronary patients with atrial fibrillation paroxysms following intravenous administration of 0.61-3.8 mg/kg Rhythmilen or its single oral dose (1.25-2.5 mg/kg), as well as during prolonged treatment with 400-600 mg Rhythmilen daily, demonstrated that their myocardial contractility parameters were reduced in the absence of an attack. Contractility parameters were not basically affected where the drug had no effect. Rhythmilen is an effective anti-arrhythmic agent: it arrests atrial fibrillation paroxysms in 73% and maintains the sinus rhythm when used preventively in 82% of cases.
D004206:Disopyramide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004452:Echocardiography; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects*; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy* / Q000503:physiopathology
D004206:Disopyramide
Ekhokardiograficheskie pokazateli funktsii serdtsa i sistemnaia gemodinamika u bol'nykh s paroksizmami mertsatel'noĭ aritmii i ikh dinamika pri vozdeĭstvii dizopiramida fosfata.